Latest Advanced Prostate Cancer News2017-10-19T10:43:14-04:00

Long-Term Results Confirm Value of Adding Radio Therapy to ADT for Prostate Cancer Survival

There were many very interesting and very important items presented at the recent ASCO GU conference. Over the course of the next week or two I will be systematically reviewing many of these finds that [...]

An Early Peek At the Phase III PREVAIL Trial of Enzalutamide (Xtandi) Results – Good For Prostate Cancer

An important update from the phase III PREVAIL study (Xtandi in the pre-chemotherapy stage) was released thsi evening (actually yesterday evening) in advance of a formal presentation this Thursday at ASCO GU. The news is [...]

NICE Changes Its Mind & Reverses Its Prior Decision on the Use of Xtandi in the UK!

Live in the UK and have advanced prostate cancer? If you do then be prepared to have economics over-ride your legitimate health concerns. The U.K.'s National Institute for Health and Care Excellence (NICE) makes no [...]

How Long Is It Safe to Take Bisphosphonates for Osteoporosis? Long Term Bisphosphonate Therapy Increases the Risk for Serious Fractures of the Femur

A John’s Hopkins Health Alert titled “How Long Is It Safe to Take Bisphosphonates for Osteoporosis?” Should Raise Some Concerns Men on Long Term Bisphosphonate Therapy Hormone therapy (ADT) is notorious for many negative side [...]

NCI Director Out of Touch with His Agency and with the Major Characteristics of Breast & Prostate Cancer Funding

Out-takes from an Interview in August 2013 with Brian Lamb, a journalist and the founder, executive chairman, and now retired CEO of C-SPAN  which provides coverage of the U,S. Congress as well as other public affairs [...]

A Statistical Nightmare – Comparing the Efficacy of Zytiga & Xtandi In the Pre-Chemo Setting

Based on the assumption that Enzalutamide (Xtandi) is approved for use in men with castrate resistant metastatic prostate cancer (advanced prostate cancer or mCRPC) who have not had prior chemotherapy, pretty much a foregone conclusion [...]

Go to Top